ideasIdea
Block the chemical switch that lets cells hide from treatment
Cells that survive treatment do so by changing which genes they use, not their DNA. Drugs that block that change may stop survivors from forming at all.
The persister state depends on chromatin regulators including KDM5A, LSD1 and BRD4, and pharmacological inhibition of these reduced persister formation in the original studies of drug-tolerant cells. The proposal is to use these inhibitors not as continuous therapy but as short pulses during the induction phase, when the persister state is being established, minimising the toxicity that has limited epigenetic drugs.
Hypothesis
Short-course epigenetic inhibition during the first weeks of targeted therapy reduces the persister population and extends time to resistance, without the cumulative toxicity of continuous dosing.
Rationale
The persister transition is a time-limited event, so exposure only needs to cover that window; epigenetic drugs have failed largely on chronic tolerability rather than lack of activity.
What would test it
Preclinical schedule optimisation comparing pulsed versus continuous epigenetic inhibition alongside a targeted agent, with persister quantification by lineage tracing, then a phase 1b pulsed schedule.
Maturity
preclinical evidence
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
6
Bottlenecks it attacks
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.